Table 1.

Six randomized, placebo-controlled trials of adjunctive BRV in patients with uncontrolled seizures

Trial	ITT population (seizure type)	Brivaracetam range	Responder rates ≥50% for PBO and BRV
French et al27	BRV 154	5–50 mg/day	16.7% for PBO
	PBO 54 (partial)		32.0% for BRV 5 mg/day*
			44.2% for BRV 20 mg/day*
			55.8% for BRV 50 mg/day*
Van Paesschen et al28	BRV 105	50–150 mg/day	17.3% for PBO
	PBO 52 (partial)		35.8% for BRV 50 mg/day*
			30.8% for BRV 150 mg/day
Ryvlin et al29	BRV 298	20–100 mg/day	20.0% for PBO
	PBO 100 (partial)		27.3% for BRV 20 mg/day
			27.3% for BRV 50 mg/day
			36.0% for BRV 100 mg/day*
Biton et al30	BRV 298	5–50 mg/day	16.7% for PBO
	PBO 98 (partial)		21.9% for BRV 5 mg/day
			23.2% for BRV 20 mg/day
			32.7% for BRV 50 mg/day*
Kwan et al31	BRV 359 (323 partial; 36 generalized)	Flexible doses	16.7% for PBO
		20–150 mg/day	30.3% in BRV group with partial seizures*
	PBO 121 (108 focal; 13 generalized)		15.4% for PBO
			44.4% in BRV group with generalized seizures
Klein et al32	BRV 501	100–200 mg/day	21.6% for PBO
	PBO 259 (partial)		38.9% for BRV 100 mg/day*
			37.8% for BRV 200 mg/day*

Notes:

^*Significantly different (P<0.05) from placebo. Copyright ©2015. Dove Medical Press. Adapted from Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015;9:5719–5725.¹¹

Abbreviations: BRV, brivaracetam; ITT, intention-to-treat; NR, not reported data; PBO, placebo.